{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:09:23Z","timestamp":1787695763373,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1708100, 2018YFC1708105"],"award-info":[{"award-number":["2018YFC1708100, 2018YFC1708105"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012326","name":"International Science and Technology Cooperation Programme","doi-asserted-by":"publisher","award":["2013DFG31080"],"award-info":[{"award-number":["2013DFG31080"]}],"id":[{"id":"10.13039\/501100012326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc; also known as \u201cscleroderma\u201d) is an autoimmune disorder characterized by extensive fibrosis, vascular changes, and immunologic dysregulation. Baicalein (phenolic flavonoid derived from <jats:italic>Scutellaria baicalensis<\/jats:italic> Georgi) has been used to treat the pathological processes of various fibrotic and inflammatory diseases. In this study, we investigated the effect of baicalein on the major pathologic characteristics of SSc: fibrosis, B-cell abnormalities, and inflammation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The effect of baicalein on collagen accumulation and expression of fibrogenic markers in human dermal fibroblasts were analyzed. SSc mice were produced by injecting bleomycin and treated with baicalein (25, 50, or 100\u00a0mg\/kg). The antifibrotic features of baicalein and its mechanisms were investigated by histologic examination, hydroxyproline assay, enzyme-linked immunosorbent assay, western blotting and flow cytometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Baicalein (5\u2013120\u00a0\u03bcM) significantly inhibited the accumulation of the extracellular matrix and fibroblast activation in transforming growth factor (TGF)-\u03b21- and platelet derived growth factor (PDGF)-induced human dermal fibroblasts, as evidenced by abrogated deposition of total collagen, decreased secretion of soluble collagen, reduced collagen contraction capability and downregulation of various fibrogenesis molecules. In a bleomycin-induced model of dermal fibrosis in mice, baicalein (25\u2013100\u00a0mg\/kg) restored dermal architecture, ameliorated inflammatory infiltrates, and attenuated dermal thickness and collagen accumulation in a dose-dependent manner. According to flow cytometry, baicalein reduced the proportion of B cells (B220<jats:sup>+<\/jats:sup> lymphocytes) and increased the proportion of memory B cells (B220<jats:sup>+<\/jats:sup>CD27<jats:sup>+<\/jats:sup> lymphocytes) in the spleens of bleomycin-induced mice. Baicalein treatment potently attenuated serum levels of cytokines (interleukin (IL)-1\u03b2, IL-2, IL-4, IL-6, IL-17A, tumor necrosis factor-\u03b1), chemokines (monocyte chemoattractant protein-1, macrophage inflammatory protein-1 beta) and autoantibodies (anti-scleroderma 70 (Scl-70), anti-polymyositis-scleroderma (PM-Scl), anti-centromeres, anti-double stranded DNA (dsDNA). In addition, baicalein treatment can significantly inhibit the activation of TGF-\u03b21 signaling in dermal fibroblasts and bleomycin-induce mice of SSc, evidenced by reducing the expression of TGF-\u03b21 and IL-11, as well as inhibiting both small mother against decapentaplegic homolog 3 (SMAD3) and extracellular signal-related kinase (ERK) activation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings suggest that baicalein has therapeutic potential against SSc, exerting modulating B-cell abnormalities, anti-inflammatory effects, and antifibrosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-023-03885-1","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T11:04:57Z","timestamp":1676977497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities"],"prefix":"10.1186","volume":"23","author":[{"given":"Bo","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"issue":"10103","key":"3885_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"9","key":"3885_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3899\/jrheum.180042","volume":"46","author":"H Al-Sheikh","year":"2019","unstructured":"Al-Sheikh H, Ahmad Z, Johnson SR. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J Rheumatol. 2019;46(9):1103\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"3885_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"key":"3885_CR4","doi-asserted-by":"publisher","first-page":"925741","DOI":"10.3389\/fimmu.2022.925741","volume":"13","author":"K Melissaropoulos","year":"2022","unstructured":"Melissaropoulos K, Iliopoulos G, Sakkas LI, Daoussis D. Pathogenetic aspects of systemic sclerosis: a view through the prism of B cells. Front Immunol. 2022;13:925741.","journal-title":"Front Immunol"},{"key":"3885_CR5","doi-asserted-by":"publisher","first-page":"118183","DOI":"10.1016\/j.lfs.2020.118183","volume":"259","author":"HS Tuli","year":"2020","unstructured":"Tuli HS, Aggarwal V, Kaur J, Aggarwal D, Parashar G, Parashar NC, Tuorkey M, Kaur G, Savla R, Sak K, et al. Baicalein: A metabolite with promising antineoplastic activity. Life Sci. 2020;259:118183.","journal-title":"Life Sci"},{"key":"3885_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejmech.2017.03.004","volume":"131","author":"B Dinda","year":"2017","unstructured":"Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 2017;131:68\u201380.","journal-title":"Eur J Med Chem"},{"key":"3885_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.phrs.2015.08.021","volume":"100","author":"MR de Oliveira","year":"2015","unstructured":"de Oliveira MR, Nabavi SF, Habtemariam S, Erdogan Orhan I, Daglia M, Nabavi SM. The effects of baicalein and baicalin on mitochondrial function and dynamics: A review. Pharmacol Res. 2015;100:296\u2013308.","journal-title":"Pharmacol Res"},{"key":"3885_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.taap.2018.09.007","volume":"358","author":"X Cui","year":"2018","unstructured":"Cui X, Sun X, Lu F, Jiang X. Baicalein represses TGF-beta1-induced fibroblast differentiation through the inhibition of miR-21. Toxicol Appl Pharmacol. 2018;358:35\u201342.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"3885_CR9","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.3892\/etm.2017.4888","volume":"14","author":"Q Hu","year":"2017","unstructured":"Hu Q, Gao L, Peng B, Liu X. Baicalin and baicalein attenuate renal fibrosis in vitro via inhibition of the TGF-beta1 signaling pathway. Exp Ther Med. 2017;14(4):3074\u201380.","journal-title":"Exp Ther Med"},{"issue":"2\u20133","key":"3885_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2011.02.033","volume":"658","author":"EK Kong","year":"2011","unstructured":"Kong EK, Yu S, Sanderson JE, Chen KB, Huang Y, Yu CM. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol. 2011;658(2\u20133):175\u201381.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"3885_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2010.01.002","volume":"631","author":"H Sun","year":"2010","unstructured":"Sun H, Che QM, Zhao X, Pu XP. Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol. 2010;631(1\u20133):53\u201360.","journal-title":"Eur J Pharmacol"},{"key":"3885_CR12","doi-asserted-by":"publisher","first-page":"110744","DOI":"10.1016\/j.biopha.2020.110744","volume":"131","author":"X Sun","year":"2020","unstructured":"Sun X, Cui X, Chen X, Jiang X. Baicalein alleviated TGF beta1-induced type I collagen production in lung fibroblasts via downregulation of connective tissue growth factor. Biomed Pharmacother. 2020;131:110744.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3885_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10735-015-9621-8","volume":"46","author":"W Wang","year":"2015","unstructured":"Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-kappaB and MAPK signal pathways. J Mol Histol. 2015;46(3):283\u201390.","journal-title":"J Mol Histol"},{"issue":"9","key":"3885_CR14","doi-asserted-by":"publisher","first-page":"15625","DOI":"10.1002\/jcb.28829","volume":"120","author":"X Yang","year":"2019","unstructured":"Yang X, Zhang C, Jiang J, Li Y. Baicalein retards proliferation and collagen deposition by activating p38MAPK-JNK via microRNA-29. J Cell Biochem. 2019;120(9):15625\u201334.","journal-title":"J Cell Biochem"},{"issue":"1","key":"3885_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/bju.13219","volume":"118","author":"W Wang","year":"2016","unstructured":"Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein ameliorates renal interstitial fibrosis by inducing myofibroblast apoptosis in vivo and in vitro. BJU Int. 2016;118(1):145\u201352.","journal-title":"BJU Int"},{"issue":"7","key":"3885_CR16","doi-asserted-by":"publisher","first-page":"e69592","DOI":"10.1371\/journal.pone.0069592","volume":"8","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Shan L, Hua Y, Wang D, Zeng H, Liu R, Zhang W, Hu Z. Baicalein selectively induces apoptosis in activated lymphocytes and ameliorates concanavalin a-induced hepatitis in mice. PLoS ONE. 2013;8(7):e69592.","journal-title":"PLoS ONE"},{"key":"3885_CR17","doi-asserted-by":"publisher","first-page":"109562","DOI":"10.1016\/j.intimp.2022.109562","volume":"114","author":"S Ying","year":"2023","unstructured":"Ying S, Yang H, Gu Q, Wu Z, Zou N, Wang CZ, Wan C, Yuan CS. The Small-Molecule compound baicalein alleviates experimental autoimmune encephalomyelitis by suppressing pathogenetic CXCR6(+) CD4 cells. Int Immunopharmacol. 2023;114:109562.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3885_CR18","first-page":"1149","volume":"18","author":"J Xu","year":"2018","unstructured":"Xu J, Liu J, Yue G, Sun M, Li J, Xiu X, Gao Z. Therapeutic effect of the natural compounds baicalein and baicalin on autoimmune diseases. Mol Med Rep. 2018;18(1):1149\u201354.","journal-title":"Mol Med Rep"},{"issue":"3","key":"3885_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M Brown","year":"2019","unstructured":"Brown M, O\u2019Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310\u201321.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"3885_CR20","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1002\/art.23806","volume":"58","author":"M Manetti","year":"2008","unstructured":"Manetti M, Neumann E, Muller A, Schmeiser T, Saar P, Milia AF, Endlicher E, Roeb E, Messerini L, Matucci-Cerinic M, et al. Endothelial\/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum. 2008;58(9):2866\u201373.","journal-title":"Arthritis Rheum"},{"key":"3885_CR21","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell JC, O\u2019Reilly S. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun. 2020;113:102526.","journal-title":"J Autoimmun"},{"issue":"6","key":"3885_CR22","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004;50(6):1918\u201327.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3885_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.autrev.2017.10.015","volume":"17","author":"A Forestier","year":"2018","unstructured":"Forestier A, Guerrier T, Jouvray M, Giovannelli J, Lefevre G, Sobanski V, Hauspie C, Hachulla E, Hatron PY, Zephir H, et al. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev. 2018;17(3):244\u201355.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"3885_CR24","first-page":"30","volume":"34 Suppl 100","author":"D Simon","year":"2016","unstructured":"Simon D, Balogh P, Bognar A, Kellermayer Z, Engelmann P, Nemeth P, Farkas N, Minier T, Lorand V, Czirjak L, et al. Reduced non-switched memory B cell subsets cause imbalance in B cell repertoire in systemic sclerosis. Clin Exp Rheumatol. 2016;34 Suppl 100(5):30\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"3885_CR25","first-page":"23","volume":"37 Suppl 119","author":"N Yagi-Numata","year":"2019","unstructured":"Yagi-Numata N, Matsushita T, Takehara K, Hamaguchi Y. Increased expression levels of FcgammaRIIB on naive and double-negative memory B cells in patients with systemic sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 119(4):23\u201331.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"3885_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/ajh\/hpu194","volume":"28","author":"AW Wang","year":"2015","unstructured":"Wang AW, Song L, Miao J, Wang HX, Tian C, Jiang X, Han QY, Yu L, Liu Y, Du J, et al. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT\/mTOR, ERK1\/2, NF-kappaB, and calcineurin signaling pathways in mice. Am J Hypertens. 2015;28(4):518\u201326.","journal-title":"Am J Hypertens"},{"issue":"50A","key":"3885_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.9734\/jpri\/2021\/v33i50A33385","volume":"33","author":"S Kulavi","year":"2021","unstructured":"Kulavi S, Banerjee S, Sengupta T, Ghosh C, Saha M, Chatterjee S. Virtual Screening through Molecular Docking Analysis to Identify Potential Natural Inhibitor (s) of Lyn Tyrosine Kinase-An In-silico Approach. J Pharm Res Int. 2021;33(50A):85\u2013105.","journal-title":"J Pharm Res Int"},{"issue":"7","key":"3885_CR28","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00296-018-4076-3","volume":"38","author":"K Melissaropoulos","year":"2018","unstructured":"Melissaropoulos K, Liossis SN. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int. 2018;38(7):1225\u201334.","journal-title":"Rheumatol Int"},{"issue":"11","key":"3885_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI0215078","volume":"109","author":"E Saito","year":"2002","unstructured":"Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Investig. 2002;109(11):1453\u201362.","journal-title":"J Clin Investig"},{"issue":"26","key":"3885_CR30","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1182\/blood-2014-08-595470","volume":"125","author":"R Flynn","year":"2015","unstructured":"Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015;125(26):4085\u201394.","journal-title":"Blood"},{"issue":"12","key":"3885_CR31","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1248\/bpb.26.1685","volume":"26","author":"M Shichijo","year":"2003","unstructured":"Shichijo M, Yamamoto N, Tsujishita H, Kimata M, Nagai H, Kokubo T. Inhibition of syk activity and degranulation of human mast cells by flavonoids. Biol Pharm Bull. 2003;26(12):1685\u201390.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"3885_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.0906-6705.2005.00280.x","volume":"14","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol. 2005;14(2):81\u201395.","journal-title":"Exp Dermatol"},{"issue":"12","key":"3885_CR33","doi-asserted-by":"publisher","first-page":"e29399","DOI":"10.1371\/journal.pone.0029399","volume":"6","author":"P Gallet","year":"2011","unstructured":"Gallet P, Phulpin B, Merlin JL, Leroux A, Bravetti P, Mecellem H, Tran N, Dolivet G. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS ONE. 2011;6(12):e29399.","journal-title":"PLoS ONE"},{"issue":"2","key":"3885_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s11926-012-0304-0","volume":"15","author":"T Iwayama","year":"2013","unstructured":"Iwayama T, Olson LE. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Curr Rheumatol Rep. 2013;15(2):304.","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"3885_CR35","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1093\/rheumatology\/keab168","volume":"60","author":"E Adami","year":"2021","unstructured":"Adami E, Viswanathan S, Widjaja AA, Ng B, Chothani S, Zhihao N, Tan J, Lio PM, George BL, Altunoglu U, et al. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFbeta-mediated activation of dermal fibroblasts. Rheumatology. 2021;60(12):5820\u20136.","journal-title":"Rheumatology"},{"issue":"9","key":"3885_CR36","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the fascinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018;77(9):1362\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3885_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1465-9921-14-80","volume":"14","author":"GE Lindahl","year":"2013","unstructured":"Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, Bou-Gharios G, Nicholson AG, Denton CP, Grutters JC, et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res. 2013;14(1):80.","journal-title":"Respir Res"},{"issue":"7","key":"3885_CR38","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10067-021-05733-4","volume":"40","author":"G De Luca","year":"2021","unstructured":"De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic Sclerosis: a \u201cmidsummer dream\u201d to extinguish inflammation and prevent early disease progression to fibrosis. Clin Rheumatol. 2021;40(7):2529\u201333.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3885_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13075-019-2074-9","volume":"21","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, Fan C, Feng C, Zuo J, Niu L, et al. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019;21(1):290.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3885_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","volume":"58","author":"A Stochmal","year":"2020","unstructured":"Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"3885_CR41","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/jid.2008.431","volume":"129","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Takeda K, Okamoto A, Matsuo S, Isobe K. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol. 2009;129(7):1688\u201395.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3885_CR42","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/jcb.24445","volume":"114","author":"J Zong","year":"2013","unstructured":"Zong J, Zhang DP, Zhou H, Bian ZY, Deng W, Dai J, Yuan Y, Gan HW, Guo HP, Tang QZ. Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1\/2 signaling. J Cell Biochem. 2013;114(5):1058\u201365.","journal-title":"J Cell Biochem"},{"issue":"6","key":"3885_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.pupt.2013.03.006","volume":"26","author":"Y Gao","year":"2013","unstructured":"Gao Y, Lu J, Zhang Y, Chen Y, Gu Z, Jiang X. Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21. Pulm Pharmacol Ther. 2013;26(6):649\u201354.","journal-title":"Pulm Pharmacol Ther"},{"key":"3885_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-041818-011649","volume":"71","author":"SA Cook","year":"2020","unstructured":"Cook SA, Schafer S. Hiding in plain sight: interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation. Annu Rev Med. 2020;71:263\u201376.","journal-title":"Annu Rev Med"},{"issue":"8","key":"3885_CR45","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1002\/art.23677","volume":"58","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, Distler O, Schett G, Distler JH. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 2008;58(8):2553\u201364.","journal-title":"Arthritis Rheum"},{"issue":"7474","key":"3885_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature12614","volume":"503","author":"EE Gerber","year":"2013","unstructured":"Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, Dietz HC. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature. 2013;503(7474):126\u201330.","journal-title":"Nature"},{"issue":"10","key":"3885_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10067-011-1766-6","volume":"30","author":"VK Shanmugam","year":"2011","unstructured":"Shanmugam VK, Swistowski DR, Saddic N, Wang H, Steen VD. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol. 2011;30(10):1363\u20138.","journal-title":"Clin Rheumatol"},{"key":"3885_CR48","first-page":"10","volume":"2019","author":"M Meng","year":"1861","unstructured":"Meng M, Tan J, Chen W, Du Q, Xie B, Wang N, Zhu H, Wang K. The fibrosis and immunological features of hypochlorous acid induced mouse model of systemic sclerosis. Front Immunol. 1861;2019:10.","journal-title":"Front Immunol"},{"key":"3885_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fimmu.2017.00053","volume":"8","author":"S Sanges","year":"2017","unstructured":"Sanges S, Jendoubi M, Kavian N, Hauspie C, Speca S, Crave JC, Guerrier T, Lefevre G, Sobanski V, Savina A, et al. B cell homeostasis and functional properties are altered in an hypochlorous acid-induced murine model of systemic sclerosis. Front Immunol. 2017;8:53.","journal-title":"Front Immunol"},{"key":"3885_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imlet.2018.01.002","volume":"195","author":"A Yoshizaki","year":"2018","unstructured":"Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76\u201382.","journal-title":"Immunol Lett"},{"issue":"6","key":"3885_CR51","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/ard.2010.137349","volume":"70","author":"V Codullo","year":"2011","unstructured":"Codullo V, Baldwin HM, Singh MD, Fraser AR, Wilson C, Gilmour A, Hueber AJ, Bonino C, McInnes IB, Montecucco C, et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis. 2011;70(6):1115\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3885_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/art.38901","volume":"67","author":"T Takahashi","year":"2015","unstructured":"Takahashi T, Asano Y, Ichimura Y, Toyama T, Taniguchi T, Noda S, Akamata K, Tada Y, Sugaya M, Kadono T, et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis & rheumatology. 2015;67(1):254\u201365.","journal-title":"Arthritis & rheumatology"},{"issue":"5","key":"3885_CR53","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","volume":"69","author":"N Dumoitier","year":"2017","unstructured":"Dumoitier N, Chaigne B, Regent A, Lofek S, Mhibik M, Dorfmuller P, Terrier B, London J, Berezne A, Tamas N, et al. Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor beta and Activate Fibroblasts. Arthritis & rheumatology. 2017;69(5):1078\u201389.","journal-title":"Arthritis & rheumatology"},{"issue":"11","key":"3885_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723\u201337.","journal-title":"Nat Rev Immunol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-03885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-03885-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-03885-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T11:06:11Z","timestamp":1676977571000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-03885-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3885"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-03885-1","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and animal experiments were reviewed and approved by the Animal Ethical and Welfare Committee of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences (Approval number: 20162032). All animals were treated in compliance with the guidelines for the care and use of laboratory animals. The study was carried out in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}